Summary
Global Markets Direct’s, ‘Galapagos NV - Product Pipeline Review - 2016’, provides an overview of the Galapagos NV’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Galapagos NV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Galapagos NV
- The report provides overview of Galapagos NV including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Galapagos NV’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Galapagos NV’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Galapagos NV’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Galapagos NV
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Galapagos NV’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Galapagos NV Snapshot 6
Galapagos NV Overview 6
Key Information 6
Key Facts 6
Galapagos NV - Research and Development Overview 7
Key Therapeutic Areas 7
Galapagos NV - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Galapagos NV - Pipeline Products Glance 17
Galapagos NV - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Galapagos NV - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Galapagos NV - Drug Profiles 21
filgotinib 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
GLPG-1205 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
GLPG-1690 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
GLPG-1837 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
DT-200 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
GLPG-1972 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GLPG-2222 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
GLPG-2451 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
MOR-106 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GLPG-1492 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GLPG-1790 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
GLPG-1837 + GLPG-2222 + GLPG-2665 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
GLPG-2534 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GLPG-2665 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
GLPG-2737 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GLPG-2851 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
GLPG-2938 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Galapagos NV - Pipeline Analysis 44
Galapagos NV - Pipeline Products by Target 44
Galapagos NV - Pipeline Products by Route of Administration 45
Galapagos NV - Pipeline Products by Molecule Type 46
Galapagos NV - Pipeline Products by Mechanism of Action 47
Galapagos NV - Recent Pipeline Updates 48
Galapagos NV - Dormant Projects 60
Galapagos NV - Discontinued Pipeline Products 61
Discontinued Pipeline Product Profiles 61
GLPG-0187 61
GLPG-0259 61
GLPG-1179 61
GLPG-1205 61
GLPG-1332 61
GLPG-1577 61
Galapagos NV - Locations And Subsidiaries 62
Head Office 62
Other Locations & Subsidiaries 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64
List of Tables
Galapagos NV, Key Information 6
Galapagos NV, Key Facts 6
Galapagos NV - Pipeline by Indication, 2016 8
Galapagos NV - Pipeline by Stage of Development, 2016 10
Galapagos NV - Monotherapy Products in Pipeline, 2016 11
Galapagos NV - Combination Treatment Modalities in Pipeline, 2016 12
Galapagos NV - Partnered Products in Pipeline, 2016 13
Galapagos NV - Partnered Products/ Combination Treatment Modalities, 2016 14
Galapagos NV - Out-Licensed Products in Pipeline, 2016 15
Galapagos NV - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
Galapagos NV - Phase II, 2016 17
Galapagos NV - Phase I, 2016 18
Galapagos NV - Preclinical, 2016 19
Galapagos NV - Discovery, 2016 20
Galapagos NV - Pipeline by Target, 2016 44
Galapagos NV - Pipeline by Route of Administration, 2016 45
Galapagos NV - Pipeline by Molecule Type, 2016 46
Galapagos NV - Pipeline Products by Mechanism of Action, 2016 47
Galapagos NV - Recent Pipeline Updates, 2016 48
Galapagos NV - Dormant Developmental Projects,2016 60
Galapagos NV - Discontinued Pipeline Products, 2016 61
Galapagos NV, Subsidiaries 62
List of Figures
Galapagos NV - Pipeline by Top 10 Indication, 2016 8
Galapagos NV - Pipeline by Stage of Development, 2016 10
Galapagos NV - Monotherapy Products in Pipeline, 2016 11
Galapagos NV - Pipeline by Target, 2016 44
Galapagos NV - Pipeline by Route of Administration, 2016 45
Galapagos NV - Pipeline by Molecule Type, 2016 46
Galapagos NV - Pipeline Products by Mechanism of Action, 2016 47
